Human Molecular Genetics Advance Access originally published online on March 16, 2005
Human Molecular Genetics 2005 14(9):1171-1182; doi:10.1093/hmg/ddi130
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Published by Oxford University Press 2005.
The role of histone acetylation in SMN gene expression
Neurogenetics Branch, National Institute of Neurological Disorders and Stroke, Bethesda, MD 20892, USA
* To whom correspondence should be addressed at: Neurogenetics Branch, NINDS, NIH, Building 35, Room 2A-1010, 35 Convent Drive, Bethesda, MD 20892, USA. Tel: +1 3014359288; Fax: +1 3014803365; Email: sumnerc{at}ninds.nih.gov
Received January 28, 2005; Accepted March 10, 2005
Increasing survival motor neuron 2 (SMN2) gene expression may be an effective strategy for the treatment of spinal muscular atrophy (SMA). Histone deacetylase (HDAC) inhibitors have been shown to increase SMN transcript and protein levels, but the specific role of histone acetylation in regulating SMN gene expression has not been explored. Using chromatin immunopreciptation, we investigated the levels of acetylated H3 and H4 histones and HDACs associated with different regions of the human and mouse SMN genes in both cultured cells and tissues. We show that the SMN gene has a reproducible pattern of histone acetylation that is largely conserved among different tissues and species. A limited region of the promoter surrounding the transcriptional start site has relatively high levels of histone acetylation, whereas regions further upstream or downstream have lower levels. After HDAC inhibitor treatment, acetylated histone levels increased, particularly at upstream regions, correlating with a 2-fold increase in promoter activity. During development in mouse tissues, histone acetylation levels decreased and associated HDAC2 levels increased at the region closest to the transcriptional start site, correlating with a 40–60% decrease in SMN transcript and protein levels. These data indicate that histone acetylation modulates SMN gene expression and that pharmacological manipulation of this epigenetic determinant is feasible. HDAC2, in particular, may be a future therapeutic target for SMA.
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  K. J. Swoboda, J. T. Kissel, T. O. Crawford, M. B. Bromberg, G. Acsadi, G. D'Anjou, K. J. Krosschell, S. P. Reyna, M. K. Schroth, C. B. Scott, et al. Perspectives on Clinical Trials in Spinal Muscular Atrophy J Child Neurol, August 1, 2007; 22(8): 957 - 966. [Abstract] [PDF]
|
|
|
|
|
|
C. J. Sumner Molecular Mechanisms of Spinal Muscular Atrophy J Child Neurol, August 1, 2007; 22(8): 979 - 989. [Abstract] [PDF]
|
|
|
|
 |
|
 C. C. Weihl, A. M. Connolly, and A. Pestronk Valproate may improve strength and function in patients with type III/IV spinal muscle atrophy Neurology, August 8, 2006; 67(3): 500 - 501. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 T. H. Gillingwater, T. M. Wishart, P. E. Chen, J. E. Haley, K. Robertson, S. H.-F. MacDonald, S. Middleton, K. Wawrowski, M. J. Shipston, S. Melmed, et al. The neuroprotective WldS gene regulates expression of PTTG1 and erythroid differentiation regulator 1-like gene in mice and human cells Hum. Mol. Genet., February 15, 2006; 15(4): 625 - 635. [Abstract] [Full Text] [PDF]
|
|